The latest information about BioMark Diagnostics to keep you up to date.
BioMark Diagnostics is leading the world in early-stage cancer detection with an oncology focus designed to improve patient outcomes.
BioMark Continues to Strengthen its Intellectual Property position With New Patent and Trademark Use in
BIOMARK ANNOUNCES CLOSING OF $1,5 MILLION FINANCING ROUND TO ACCELERATE COMMERCIALIZATION OF ITS LIQUID BIOPSY
FORM 7MONTHLY PROGRESS REPORT Name of Listed Issuer: BioMark Diagnostics Inc. _____ (the
BIOMARK TO PRESENT NEW CANCER SCREENING DATA USING THE LDTD-MS/MS TECHNIQUE AT THE ANNUAL ASMS
FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed
Vancouver, British Columbia – (June 29th, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE:
Vancouver, British Columbia – (June 1st, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE:
Vancouver, Colombie-Britannique – (1er juin 2021) – BioMark Diagnostics Inc. («BioMark») (CSE: BUX) (FSE: 20B)
No paperwork, no hassle. We keep things digital, easy and regular.
*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.
1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2
Rashid A. Bux (CEO)
[email protected]
